Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma

Fu, Yucheng; Lan, Tao; Cai, Hongliu; Lu, A.C.W.; Yu, Wei

doi:10.1097/md.0000000000010741

Cited by 47 publications

(42 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our own cases, abnormal levels of ALP and LDH were found for the first time to be related to MD and negatively influence the prognosis of SCOS, in accordance with previous findings in patients with conventional osteosarcoma [72] , [73] . Meta-analyses demonstrated that ALP and LDH were related with poor prognosis in osteosarcoma patients, including event-free survival and overall survival [74] , [75] . Many researchers thought higher serum ALP and LDH level meant heavier osteosarcoma burden, which implied worse prognosis [74] , [75] .…”

Section: Discussionmentioning

confidence: 99%

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

Zhong

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

Introduction Small cell osteosarcoma (SCOS) is a rare subtype of osteosarcoma, with limited studies mainly focusing on histological features. Our study aims to analyze our own patients and those reported in the literature to increase the recognition of this rare disease, to evaluate patient survival and to further determine potential prognostic factors. Material and methods Twenty patients with SCOS were treated in our hospital between 2010 and 2019. Their follow-up data were collected retrospectively. A total of 336 literature cases from 58 manuscripts were retrieved by means of a PubMed search with the key word “small cell osteosarcoma”. Data pertaining to treatment and follow-up were extracted. We performed a pooled analysis for the survival of patients and the risk factors for local recurrence (LR), as well as metastatic disease (MD), in a total of 160 patients using the Kaplan-Meier method and Cox regression method. Results We reported our experience in diagnosing and treating SCOS. In our cases, elevated alkaline phosphatase (P = 0.013) and lactate dehydrogenase (P = 0.001) significantly impaired overall survival. In the pooled analysis, SCOS was diagnosed at the median age of 17 years and affected both sexes almost equally. The median follow-up duration was 19.5 months. In the pooled analysis cases, the 5-year overall survival rate was 38.6%, and 36.4% of patients survived 10 years. However, an increasing trend was detected, indicating recent improvements in management. The surgical margin status (P = 0.024) and metastases (P = 0.008) significantly impaired overall survival, and the response to chemotherapy was related to disease-free survival (P = 0.012). LR and MD were significantly correlated (P = 0.002) and could be observed after 5 years of follow-up. LR was significantly dependent on response to chemotherapy (P = 0.020). The development of MD seemed to be affected by response to chemotherapy (P = 0.060). Correlations between imaging features and prognosis were not detected. Conclusions This study suggested that positive margins, poor response to chemotherapy and MD are negative prognostic factors for SCOS, implied the potential role of laboratory examinations in the survival prediction and supported the need for prolonged or more intensive surveillance in patients with MD or LR. More well-documented literatures are encouraged to allow further confirmations.

show abstract

Section: Discussionmentioning

confidence: 99%

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

Zhong

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…There are several studies on the prognostic value of LDH levels, supported by systematic reviews/meta-analyses (132). As examples, higher pretreatment LDH concentration is associated with increased risk of overall mortality in lung cancer patients (133), high LDH serum levels are associated with lower event-free survival (EFS) in osteosarcoma patients (134) and with overall survival (OS)/progression-free survival (PFS) in urinary system cancer patients (135). Besides serum LDH, LDHA levels in cancer tissues have been reported as a biomarker of malignancy and prognosis (136).…”

Section: Lactate Metabolism As a Prognostic And Therapeutic Toolmentioning

confidence: 99%

Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy

et al. 2020

View full text Add to dashboard Cite

To sustain their high proliferation rates, most cancer cells rely on glycolytic metabolism, with production of lactic acid. For many years, lactate was seen as a metabolic waste of glycolytic metabolism; however, recent evidence has revealed new roles of lactate in the tumor microenvironment, either as metabolic fuel or as a signaling molecule. Lactate plays a key role in the different models of metabolic crosstalk proposed in malignant tumors: among cancer cells displaying complementary metabolic phenotypes and between cancer cells and other tumor microenvironment associated cells, including endothelial cells, fibroblasts, and diverse immune cells. This cell metabolic symbiosis/slavery supports several cancer aggressiveness features, including increased angiogenesis, immunological escape, invasion, metastasis, and resistance to therapy. Lactate transport is mediated by the monocarboxylate transporter (MCT) family, while another large family of G protein-coupled receptors (GPCRs), not yet fully characterized in the cancer context, is involved in lactate/acidosis signaling. In this mini-review, we will focus on the role of lactate in the tumor microenvironment, from metabolic affairs to signaling, including the function of lactate in the cancer-cancer and cancer-stromal shuttles, as well as a signaling oncometabolite. We will also review the prognostic value of lactate metabolism and therapeutic approaches designed to target lactate production and transport.

show abstract

“…However, the patients who occurred in chemo-resistance and lung metastasis always had an unfavorable prognosis, with the markedly decreased 5-year survival rate to nearly 20% 3 . Despite having unsatisfactory sensitivity and specificity, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) are still the most common serum markers used for diagnosing OS 4 - 7 . Therefore, it is very critical for OS patients to find some novel efficient biomarkers and targets for early diagnosis and treatment 8 .…”

Section: Introductionmentioning

confidence: 99%

A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma

Zhu¹,

Zhang²,

Hu³

et al. 2018

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Chemo-resistance and lung metastasis have been the two obstacles in the osteosarcoma (OS) treatment, which is still lack of effective biomarkers for prediction, diagnosis and treatment. Circular RNA (circRNA) is a new type of endogenous noncoding RNA that could serve as ideal biomarkers in cancer because of its stable loop structure. However, little is known about the diagnostic value of circRNAs in OS as well as their associations with clinicopathologic characteristics of OS patients. In the current study, we identified a novel circRNA, hsa_circ_0081001, screened by the RNA sequencing in the three paired chemo-resistant and chemo-sensitive OS cell lines (MG63/DXR vs MG63, KHOS/DXR vs KHOS, U2OS/DXR vs U2OS), and found that hsa_circ_0081001 was significantly up-regulated in the OS cell lines, tissues and serums, associated with poor overall survival and cox multivariate analysis showed that hsa_circ_0081001 was a novel independent prognostic factor for OS patients. Then, receiver operating characteristic (ROC) curve analysis revealed that hsa_circ_0081001 could act as a biomarker for the OS diagnosis and prognosis prediction, better than alkaline phosphatase (ALP) and lactate dehydrogenase (LDH). In addition, we preliminarily found that hsa_circ_0081001 expression level may dynamically monitor and reflect the condition changes of OS patients in a small-scale prospective clinical pretest. In conclusion, our study suggested that circulating hsa_circ_0081001 could serve as a potential biomarker and therapeutic target for OS patients.

show abstract

Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma

Cited by 47 publications

References 40 publications

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

Clarifying prognostic factors of small cell osteosarcoma: A pooled analysis of 20 cases and the literature

Lactate Beyond a Waste Metabolite: Metabolic Affairs and Signaling in Malignancy

A novel circulating hsa_circ_0081001 act as a potential biomarker for diagnosis and prognosis of osteosarcoma

Contact Info

Product

Resources

About